Close Menu

legal settlement

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced a settlement with Carestream Health, ending a legal dispute over imaging technologies.

The settlement and licensing deal covers a patent for analyzing non-coding DNA sequences. Navigenics had been one of 10 defendants in a lawsuit filed by Genetic Technologies alleging infringement of the patent.

The genetic testing company said in its Form 10-Q that it has settled a lawsuit in which it alleged Incyte was paid royalties for which it was not entitled.

Genetic Technologies said it has secured A$14.5 million ($15.2 million) in licensing revenues since it filed its lawsuit in February 2010.

Genetic Technologies granted a non-exclusive license to Orchid Cellmark for a number of patents covering non-coding analysis, gene mapping, and internal standards.

The suit was filed in early November and accused PacBio of luring away at least 15 of Affymetrix's former employees.

The offer was extended to Dec. 16, so investors can consider disclosures in an amended SEC filing related to a settlement with shareholders.

Proteome Sciences had sued Sanofi-Aventis for breach of contract and statutory obligations in connection to a sales and transfer agreement which concerned a share and a limited partnership interest in Xzillion Proteomics.

The firm also raised around $1.7 million through a warrant conversion tied to a 2007 private placement.

The settlement ends a dispute over distribution rights to two DxS assays, with both firms having the right to distribute the products.

Pages

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.